Study Finds Elevated Acute Stress Risk in Patients With Autoimmune Blistering Diseases

The psychological toll of autoimmune blistering diseases (AIBDs) has long been recognized, but the specific contribution of trauma- and stressor-related disorders has remained poorly characterized.¹ A recently published case-control study in The Journal of Dermatology sought to address that gap, finding that both pemphigus vulgaris and bullous pemphigoid (BP) are independently associated with significantly elevated odds of acute stress disorder (ASD)—a finding that carries meaningful clinical implications for how dermatologists approach the mental health needs of this patient population.²

Study Design and Cohort

Investigators at Robert Wood Johnson Medical School and collaborating institutions conducted a nested case-control study using the NIH's All of Us (AoU) Research Program database. The cohort comprised 165 patients with pemphigus vulgaris and 250 with pemphigoid—of whom 144 had BP, 66 had mucous membrane pemphigoid, and 40 had unspecified pemphigoid. Cases were matched approximately 1:5 to controls by age, race, and sex at birth using nearest-neighbor propensity matching, yielding 822 and 1,245 matched controls, respectively.

Three psychiatric comorbidities were evaluated: ASD (symptom duration under 1 month), PTSD (1 month or longer), and generalized anxiety disorder (GAD, 6 months or longer). Diagnoses were assessed once per patient, based on the presence of a recorded code following the initial AIBD diagnosis. Odds ratios with 95% confidence intervals were calculated using chi-square and Fisher's exact tests.

Key Findings

The headline result was a significantly increased odds of comorbid ASD in both disease groups. Patients with pemphigus had more than twice the odds of ASD compared with matched controls (OR 2.09; 95% CI 1.02–4.30; p=0.045), while pemphigoid patients showed an even stronger signal (OR 2.57; 95% CI 1.30–5.08; p<0.0065).

In contrast, neither GAD nor PTSD was significantly elevated in either group. GAD odds were essentially neutral in pemphigus (OR 1.03; p=0.928) and showed a trend toward reduction in pemphigoid (OR 0.52; p=0.052). PTSD was similarly non-significant across both conditions.

A subgroup analysis controlling for H02-class immunosuppressants, including systemic corticosteroids, found that the ASD association was no longer statistically significant, and that GAD odds were actually lower in pemphigoid patients compared with controls (OR 0.38; p=0.004). The authors suggest this pattern may reflect a modulatory effect of immunosuppressant therapy on psychiatric comorbidity—or alternatively, that corticosteroid-associated neuropsychiatric effects, including anxiety, mood disturbance, and insomnia, may confound the primary analysis.

Clinical Implications

The predominance of ASD rather than PTSD or GAD may be clinically meaningful. ASD is time-limited by definition, emerging within days to weeks of a traumatic or highly stressful event and resolving within 1 month. Its elevation in both pemphigus and BP cohorts points to a defined, potentially actionable window—around the time of new diagnosis or acute disease flare—where early psychological intervention may be especially impactful.

The authors propose a plausible bidirectional mechanism: stress drives immune dysregulation through HPA axis activation, Th1/Th2 imbalance, and proinflammatory cytokine release, including IL-6 and TNF-α, each of which has been implicated in AIBD pathogenesis. Conversely, the visible, disfiguring nature of blistering disease—combined with unpredictable relapses and prolonged treatment—may itself generate and sustain psychological stress, reinforcing a self-perpetuating cycle.

Limitations and Takeaways

The authors acknowledge meaningful constraints, including the retrospective design, reliance on administrative coding, and the absence of longitudinal psychiatric assessment. Because psychiatric diagnoses were defined relative to the AIBD diagnosis date but not tracked over time, the ability to determine true onset, chronicity, or causal direction remains limited.

Despite these caveats, the findings reinforce a growing call for integrated psychodermatologic care. Dermatologists managing patients with pemphigus or BP are well positioned to screen for signs of acute stress, facilitate timely mental health referral, and engage multidisciplinary teams when psychiatric distress is identified. Recognizing trauma-related psychopathology as a distinct and potentially modifiable dimension of AIBD burden may ultimately improve both quality of life and disease outcomes for this vulnerable population.

References

1. White MA, Hoffman VM, Yale M, Strong R, Tomayko MM. Psychosocial burden of autoimmune blistering diseases: A comprehensive survey study. J Eur Acad Dermatol Venereol. 2025;39(2):350-356. doi:10.1111/jdv.20156
2. Tan IJ, Pathak GN, Pathak SS, Rao BK, Jafferany M. Association of comorbid trauma and stressor-related disorders in pemphigus and pemphigoid: A case-control study. J Dermatol. Published online April 6, 2026. doi:10.1111/1346-8138.70260